Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto

Translated title of the contribution: Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose

Massimiliano Lanzafame, Emanuela Lattuada, Fabiana Corsini, Ercole Concia, Sandro Vento

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We report our experience of reduced atazanavir dose in 6 HIV-infected patients on their first antiretroviral regimen, naïve to protease inhibitors and with no PI resistance mutations. In spite of plasmatic trough concentrations of atazanavir below the suggested minimum effective level in all of them, virological suppression (HIV-RNA <50 copies/mL) was obtained and persisted in all patients for a fairly long time. Despite the paucity of cases, this lends weight to the clinical importance of atazanavir MEC which is still being debated.

Translated title of the contributionPharmacokinetic exposure and virological efficacy of a reduced atazanavir dose
Original languageItalian
Pages (from-to)293-295
Number of pages3
JournalInfezioni in Medicina
Volume20
Issue number4
Publication statusPublished - Dec 1 2012

Keywords

  • Atazanavir
  • Ctrough
  • HAART
  • HIV
  • Pharmacokinetics
  • Virological response

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose'. Together they form a unique fingerprint.

  • Cite this

    Lanzafame, M., Lattuada, E., Corsini, F., Concia, E., & Vento, S. (2012). Analisi farmacocinetica ed efficacia virologica di atazanavir a dosaggio ridotto. Infezioni in Medicina, 20(4), 293-295.